Efficacy and safety of adalimumab in a patient with ankylosing spondylitis on peritoneal dialysis

The most commonly used treatments in patients with ankylosing spondylitis include nonsteroidal anti-inflammatory and disease modifying anti-rheumatic drugs (DMARDs), but most of these have nephrotoxic effects. In patients who undergo chronic hemodialysis, DMARDs are not widely preferred due to the chance of increased adverse effect incidence and the risk on patient survival, in addition to already present immunosuppression. The efficacy and safety of anti-TNF alpha drugs for the treatment of renal dysfunction that develops associated to secondary amyloidosis in inflammatory rheumatic diseases have been reported in various studies. In this report, the efficacy and safety of adalimumab was shown in patients with active ankylosing spondylitis who undergo peritoneal dialysis because of chronic renal failure.